Page 2350 - Williams Hematology ( PDFDrive )

2324 Part XII: Hemostasis and Thrombosis Chapter 135: Fibrinolysis and Thrombolysis 2325

344. Hacke W, Donnan G, Fieschi C, et al: Association of outcome with early stroke treat- 374. Qureshi AI, Ali Z, Suri MF, et al: Intra-arterial third-generation recombinant tissue
ment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 49:41–48,
363:768–774, 2004. 2001.
345. Hacke W, Kaste M, Bluhmki E, et al: Thrombolysis with alteplase 3 to 4.5 hours after 375. Seitz RJ, Hamzavi M, Junghans U, et al: Thrombolysis with recombinant tissue plas-
acute ischemic stroke. N Engl J Med 359:1317–1329, 2008. minogen activator and tirofiban in stroke: Preliminary observations. Stroke 34:1932–
346. Davis SM, Donnan GA, Parsons MW, et al: Effects of alteplase beyond 3 h after stroke 1935, 2003.
in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo- 376. Seitz RJ, Meisel S, Moll M, et al: The effect of combined thrombolysis with rtPA and
controlled randomised trial. Lancet Neurol 7:299–309, 2008. tirofiban on ischemic brain lesions. Neurology 62:2110–2112, 2004.
347. Wahlgren N, Ahmed N, Davalos A, et al: Thrombolysis with alteplase 3–4.5 h after acute 377. Straub S, Junghans U, Jocanovic V, et al: Systemic thrombolysis with recombinant tissue
ischaemic stroke (SITS-ISTR): An observational study. Lancet 372:1303–1309, 2008. plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke
348. Ahmed N, Wahlgren N, Grond M, et al: Implementation and outcome of thromboly- 35:705–709, 2004.
sis with alteplase 3–4.5 h after an acute stroke: An updated analysis from SITS-ISTR. 378. Adams HP Jr, Adams RJ, Brott T, et al: Guidelines for the early management of patients
Lancet Neurol 9:866–874, 2010. with ischemic stroke: A scientific statement from the Stroke Council of the American
349. Lees KR, Bluhmki E, von Kummer R, et al: Time to treatment with intravenous Stroke Association. Stroke 34:1056–1083, 2003.
alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, 379. Broderick JP, Hacke W: Treatment of acute ischemic stroke: Part I: Recanalization strat-
NINDS, and EPITHET trials. Lancet 375:1695–1703, 2010. egies. Circulation 106:1563–1569, 2002.
350. Donnan GA, Davis SM, Chambers BR, et al: Streptokinase for acute ischemic stroke 380. Kaste M, Thomassen L, Grond M, et al: Thrombolysis for acute ischemic stroke:
with relationship to time of administration: Australian Streptokinase (ASK) Trial Study A consensus statement of the 3rd Karolinska Stroke Update, October 30–31, 2000.
Group. JAMA 276(12):961–966, 1996. Stroke 32:2717–2718, 2001.
351. Randomised controlled trial of streptokinase, aspirin, and combination of both in treat- 381. Brogden RN, Speight TM, Avery GS: Streptokinase: A review of its clinical pharmacol-
ment of acute ischaemic stroke. Multicentre Acute Stroke Trial–Italy (MAST-I) Group. ogy, mechanism of action and therapeutic uses. Drugs 5:357–445, 1973.
Lancet 346:1509–1514, 1995. 382. Dotter CT, Rosch J, Seaman AJ: Selective clot lysis with low-dose streptokinase. Radiology
352. Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter 111:31–37, 1974.
Acute Stroke Trial—Europe Study Group. N Engl J Med 335:145–150, 1996. 383. Ouriel K: Current status of thrombolysis for peripheral arterial occlusive disease. Ann
353. Parsons M, Spratt N, Bivard A, et al: A randomized trial of tenecteplase versus alteplase Vasc Surg 16:797–804, 2002.
for acute ischemic stroke. N Engl J Med 366:1099–1107, 2012. 384. Ouriel K, Shortell CK, DeWeese JA, et al: A comparison of thrombolytic therapy with
354. Barnwell SL, Clark WM, Nguyen TT, et al: Safety and efficacy of delayed intraarterial operative revascularization in the initial treatment of acute peripheral arterial ischemia.
urokinase therapy with mechanical clot disruption for thromboembolic stroke. AJNR J Vasc Surg 19:1021–1030, 1994.
Am J Neuroradiol 15:1817–1822, 1994. 385. Results of a prospective randomized trial evaluating surgery versus thrombolysis for
355. Barr JD, Mathis JM, Wildenhain SL, et al: Acute stroke intervention with intraarterial ischemia of the lower extremity. The STILE trial. Ann Surg 220:251–266, 1994.
urokinase infusion. J Vasc Interv Radiol 5(5):705–713, 1994. 386. Ouriel K, Veith FJ, Sasahara AA: Thrombolysis or peripheral arterial surgery: Phase I
356. Casto L, Caverni L, Camerlingo M, et al: Intra-arterial thrombolysis in acute ischaemic results. TOPAS Investigators. J Vasc Surg 23:64–73, 1996.
stroke: Experience with a superselective catheter embedded in the clot. J Neurol Neuro- 387. Ouriel K, Veith FJ, Sasahara AA: A comparison of recombinant urokinase with vascular
surg Psychiatry 60:667–670, 1996. surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or
357. Jansen O, von Kummer R, Forsting M, et al: Thrombolytic therapy in acute occlusion Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med 338:1105–1111, 1998.
of the intracranial internal carotid artery bifurcation. AJNR Am J Neuroradiol 16:1977– 388. Castaneda F, Swischuk JL, Li R, et al: Declining-dose study of reteplase treatment for
1986, 1995. lower extremity arterial occlusions. J Vasc Interv Radiol 13:1093–1098, 2002.
358. Nesbit GM, Clark WM, O’Neill OR, Barnwell SL: Intracranial intraarterial thromboly- 389. Ouriel K, Katzen B, Mewissen M, et al: Reteplase in the treatment of peripheral arterial
sis facilitated by microcatheter navigation through an occluded cervical internal carotid and venous occlusions: A pilot study. J Vasc Interv Radiol 11:849–854, 2000.
artery. J Neurosurg 84:387–392, 1996. 390. Ouriel K, Kandarpa K, Schuerr DM, et al: Prourokinase versus urokinase for recanal-
359. Tarr R, Taylor CL, Selman WR, et al: Good clinical outcome in a patient with a large ization of peripheral occlusions, safety and efficacy: The PURPOSE trial. J Vasc Interv
CT scan hypodensity treated with intra-arterial urokinase after an embolic stroke. Radiol 10:1083–1091, 1999.
Neurology 47:1076–1078, 1996. 391. Heymans S, Vanderschueren S, Verhaeghe R, et al: Outcome and one year follow-up of
360. Janjua N, Brisman JL: Endovascular treatment of acute ischaemic stroke. Lancet Neurol intra-arterial staphylokinase in 191 patients with peripheral arterial occlusion. Thromb
6:1086–1093, 2007. Haemost 83:666–671, 2000.
361. Liu M, Wardlaw J: Thrombolysis (different doses, routes of administration and agents) 392. Duda SH, Tepe G, Luz O, et al: Peripheral artery occlusion: Treatment with abciximab
for acute ischaemic stroke. Cochrane Database Syst Rev (2):CD000514, 2000. plus urokinase versus with urokinase alone—A randomized pilot trial (the PROMPT
362. Wardlaw JM, Del Zoppo G, Yamaguchi T, Berge E: Thrombolysis for acute ischaemic Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombo-
stroke. Cochrane Database Syst Rev (3):CD000213, 2003. sis. Radiology 221:689–696, 2001.
363. del Zoppo GJ, Higashida RT, Furlan AJ, et al: PROACT: A phase II randomized trial of 393. Drescher P, McGuckin J, Rilling WS, Crain MR: Catheter-directed thrombolytic ther-
recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery apy in peripheral artery occlusions: Combining reteplase and abciximab. AJR Am
stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke J Roentgenol 180:1385–1391, 2003.
29:4–11, 1998. 394. Cohen LH, Kaplan M, Bernhard VM: Intraoperative streptokinase. An adjunct to
364. Furlan A, Higashida R, Wechsler L, et al: Intra-arterial prourokinase for acute ischemic mechanical thrombectomy in the management of acute ischemia. Arch Surg 121:
stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral 708–715, 1986.
Thromboembolism. JAMA 282:2003–2011, 1999. 395. Comerota AJ, White JV, Grosh JD: Intraoperative intra-arterial thrombolytic therapy
365. Ogawa A, Mori E, Minematsu K, et al: Randomized trial of intraarterial infusion of for salvage of limbs in patients with distal arterial thrombosis. Surg Gynecol Obstet
urokinase within 6 hours of middle cerebral artery stroke: The middle cerebral artery 169:283–289, 1989.
embolism local fibrinolytic intervention trial (MELT) Japan. Stroke 38:2633–2639, 396. Parent FN, Bernhard VM, Pabst TS, et al: Fibrinolytic treatment of residual thrombus
2007. after catheter embolectomy for severe lower limb ischemia. J Vasc Surg 9:153–160, 1989.
366. Broderick JP: William M. Feinberg Lecture: Stroke therapy in the year 2025: Burden, 397. Quinones-Baldrich WJ, Zierler RE, Hiatt JC: Intraoperative fibrinolytic therapy: An
breakthroughs, and barriers to progress. Stroke 35:205–211, 2004. adjunct to catheter thromboembolectomy. J Vasc Surg 2:319–326, 1985.
367. Kleindorfer D, Khoury J, Alwell K, et al: Eligibility for rt-PA in acute ischemic stroke: A 398. Vedantham S, Vesely TM, Parti N, et al: Lower extremity venous thrombolysis with
population-based study. Stroke 34:281, 2003. adjunctive mechanical thrombectomy. J Vasc Interv Radiol 13:1001–1008, 2002.
368. Kothari RU, Pancioli A, Liu T, Brott T, Broderick J: Cincinnati Prehospital Stroke Scale: 399. Berridge DC, Kessel D, Robertson I: Surgery versus thrombolysis for acute limb
Reproducibility and validity. Ann Emerg Med 33:373–378, 1999. ischaemia: Initial management. Cochrane Database Syst Rev (3):CD002784, 2002.
369. Albers GW, Thijs VN, Wechsler L, et al: Magnetic resonance imaging profiles predict 400. Kessel D, Berridge D, Robertson I: Infusion techniques for peripheral arterial throm-
clinical responses to early reperfusion: The diffusion and perfusion imaging evaluation bolysis. Cochrane Database Syst Rev 1:CD000985, 2004.
for understanding stroke evolution (DEFUSE) study. Ann Neurol 60:508–517, 2006. 401. Thrombolysis in the management of lower limb peripheral arterial occlusion—A con-
370. Furlan A, Eyding D, Albers GW, et al: Dose Escalation of Desmoteplase for Acute Ische- sensus document. Working Party on Thrombolysis in the Management of Limb Ische-
mic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. mia. Am J Cardiol 81:207–218, 1998.
Stroke 37:1227–1231, 2006. 402. Hirsch AT, Haskal ZJ, Hertzer NR, et al: ACC/AHA 2005 practice guidelines for the
371. Hacke W, Albers G, Al-Rawi Y, et al: The Desmoteplase on Acute Ischemic Stroke Trial management of patients with peripheral arterial disease (lower extremity, renal, mesen-
(DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with teric, and abdominal aortic): A collaborative report. Circulation 113:e463–e654, 2006.
intravenous desmoteplase. Stroke 36:66–73, 2005. 403. Alonso-Coello P, Bellmunt S, McGorrian C, et al: Antithrombotic therapy in peripheral
372. Abciximab in Ischemic Stroke Investigators: Abciximab in acute ischemic stroke: A artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: Amer-
randomized, double-blind, placebo-controlled, dose-escalation study. Stroke 31(3): ican College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest
601–609, 2000. 141:e669S–e690S, 2012.
373. Qureshi AI, Suri MF, Khan J, et al: Abciximab as an adjunct to high-risk carotid or 404. Menon KV, Shah V, Kamath PS: The Budd-Chiari syndrome. N Engl J Med 350(6):578–
vertebrobasilar angioplasty: Preliminary experience. Neurosurgery 46:1316–1324, 2000. 585, 2004.

Kaushansky_chapter 135_p2303-2326.indd 2324 9/18/15 5:14 PM